Could a sugar pill replace insulin shots for tiny preemies?

NCT ID NCT05687500

Ongoing Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests whether an oral liquid form of glibenclamide can safely control high blood sugar in very premature infants (born before 32 weeks, weighing under 1.5 kg). The goal is to see if it can replace insulin injections. The trial involves 35 babies and monitors blood sugar control over 72 hours, watching for side effects like severe low blood sugar.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: glibenclamide (oral suspension)
What this could lead to: If successful, this could offer a simpler, oral alternative to insulin for managing high blood sugar in premature babies.
What could go wrong: This is a small, early-phase trial with only 35 infants. The drug may not control blood sugar well enough, or could cause dangerously low blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIBENCLAMIDE ADVERSE REACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypoglycemia Premature Birth

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIBENCLAMIDE ADVERSE REACTION PRETERM TRANSIENT; HYPOGLYCEMIA, NEONATAL

Contacts and locations

Locations

Hopital Necker - Enfants malades

Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.